33results about How to "Enhance mobilization" patented technology

The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.

The invention is directed to stable and labile crosslinked water swellable polymeric microparticles that can be further gelled, methods for making same, and their various uses in the hygiene and medical arts, gel electrophoresis, packaging, agriculture, the cable industry, information technology, in the food industry, papermaking, use as flocculation aids, and the like. More particularly, the invention relates to a composition comprising expandable polymeric microparticles having labile crosslinkers and stable crosslinkers, said microparticle mixed with a fluid and an unreacted tertiary crosslinker comprising PEI or other polyamine based tertiary crosslinker that is capable of further crosslinking the microparticle on degradation of the labile crosslinker and swelling of the particle, so as to form a stable gel. A particularly important use is as an injection fluid in petroleum production, where the expandable polymeric microparticles are injected into a well and when the heat and/or pH of the well cause degradation of the labile crosslinker and when the microparticle expands, the tertiary crosslinker crosslinks the polymer to form a stable gel, thus diverting water to lower permeability regions and improving oil recovery.

Lipid compositions comprising specific mixtures of edible synthetic triglycerides are provided that are useful in formulating food products having highly desirable dietary benefits. The novel lipid compositions allow simultaneous access to highly desirable dietary benefits such as delivery of calorie reduction, weight management, health benefits, or any combination thereof, and they also may be formulated trans-fatty acid free.

A system and method are provided for monitoring, collecting and aggregating position information from multiple independent data sources to localize a position of an aircraft operating worldwide. The localized position information is provided to one or more end-users or stakeholders in a format for direct integration into one or more mapping and/or situational awareness display applications. Information is collected from a plurality of monitored data sources. Weighted values are applied to certain of the information collected from the plurality of data sources according to known or predictable/determinable static and/or dynamic accuracy errors and latencies of the information provided. A detailed analytic algorithm is applied to provide a probabilistic analysis that results in a resolution of a real-time, or near real-time, aircraft location, as well as an ability to accurately predict an aircraft location along a track at some future time.

The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and/or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and/or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of TXNIP and/or an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of TRX is/are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and/or activity and/or level and/or TRX expression and/or activity and/or level for use in such therapeutic and prophylactic methods.

A method and device are disclosed for monitoring and/or altering an immune function. The method uses a resonance modulating compound as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. The resonance modulator has electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of the resonance modulator are aryl hydrazones. The described aryl nitrohydrazones have the ability to interact with populations of cells with emergent behavioral characteristics associated with chemical, biological and radiation changes and injury. The disclosure also provides numerous other examples of resonance modulating agents, and provides attributes of these agents and assays for identifying additional resonance modulating agents.

The invention features enriched Hox11+ stem cell compositions and methods of preparing and using the same. In particular, the enriched Hox11+ stem cell composition can be used for treating medical conditions, diseases, or disorders, for transplantation and transplantation therapy, and for cellular, tissue, or organ repair or regeneration.

A system and method for remediation of polluted sites, implementing a combination of chemical and biological breakdown modes on the contaminating compounds. The system includes at least one reactor for production in situ of reagents required for the breakdown modes. The reactor includes at least three types of substantially independent electro-cells for production of Fenton reagents and dissolved oxygen. The method according to the invention includes utilizing at least one reactor which comprised of substantially independent electro-cells for producing reagents required for remediation of the polluted sites and a computerized controller loaded with data obtained from a site survey, measurements made by instruments and programmed sequence.

The existing remediation techniques encounter in serious difficulties due to poor process control. Using the system according to the present invention allows control of the parameters and acceleration of the remediation process.

The #β-hemoglobinopathies #β-thalassemia (BT) and sickle cell disease (SCD) are the most frequent genetic disorders worldwide. These diseases are caused by mutations causing reduced or abnormal synthesis of the β-globin chain of the adult hemoglobin (Hb) tetramer. Here, the inventors intend to improve HSC-based gene therapy for β-thalassemia and SCD by developing an innovative, highly infectious LV vector expressing a potent anti-sickling β-globin transgene and a second biological function either increasing fetal γ-globin expression (for β-thalassemia and SCD). More particularly, the inventors have designed a novel lentivirus (LV), which carry two different functions: βAS3 gene addition and gene silencing. This last strategy allows the re-expression of the fetal γ-globin genes (HBG1 and HBG2) and production of the endogenous fetal hemoglobin (HbF). Elevated levels of HbF and HbAS3 (Hb tetramer containing βAS3-globin) will benefit the β-hemoglobinopathy phenotype by increasing the total amount of β-like globin that will: (i) reduce the alpha precipitates and improve the alpha/non alpha ratio in β-thalassemia, and (ii) reduce the sickling in SCD. This combined strategy will improve the β-hemoglobinopathy phenotype at a lower vector copy number (VCN) per cell compared to a LV expressing the βAS3 alone.

The clinical severity of β-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal γ-globin chain production at adult age, a condition termed hereditary persistence of fetal hemoglobin (HPFH). Here, the inventors have compared the extent of fetal hemoglobin (HbF) de-repression following CRISPR/Cas9-mediated targeting of different regions of the HBG1 and HBG2 promoters in an adult erythroid cell line (HUDEP-2). They achieved a potent and pancellular HbF re-activation upon disruption of binding sites for γ-globin repressors located in both HBG1 and HBG2 genes. They validated these findings in Red Blood Cells (RBCs) derived from genome edited Sickle Cell Disease (SCD) patient hematopoietic stem/progenitor cells. Overall, this study identified a binding site for an HbF repressor as a novel and potent target for the treatment of β-hemoglobinopathies. Accordingly, the present invention relates to a method for increasing fetal hemoglobin content in a eukaryotic cell comprising the step of disrupting the binding site for Leukemia/lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter.

The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.

This invention relates to a stabilizer (10) for a steerable drilling system, in particular for use in drilling directional boreholes for oil and gas extraction. There is provided a stabilizer (10) for a steerable drilling system having a first passageway (16) and a second passageway (18) at its outer surface, the passageways being helical and extending along the length of the stabilizer, the first and second passageways being oppositely-oriented, the first and second passageways intersecting one another, the stabilizer having a number of blades (22) between the passageways, the cross-sectional area of the first passageway being larger than the cross-sectional area of the second passageway. The asymmetric passageways enable the stabilizer designer to enhance the performance of the stabilizer during drilling and tripping.